These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 32738448)
1. Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity. Zhang S; Guo F; Yu M; Yang X; Yao Z; Li Q; Wei Z; Feng K; Zeng P; Zhao D; Li X; Zhu Y; Miao QR; Iwakiri Y; Chen Y; Han J; Duan Y J Hepatol; 2020 Dec; 73(6):1482-1495. PubMed ID: 32738448 [TBL] [Abstract][Full Text] [Related]
2. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. Benhamed F; Denechaud PD; Lemoine M; Robichon C; Moldes M; Bertrand-Michel J; Ratziu V; Serfaty L; Housset C; Capeau J; Girard J; Guillou H; Postic C J Clin Invest; 2012 Jun; 122(6):2176-94. PubMed ID: 22546860 [TBL] [Abstract][Full Text] [Related]
3. Liver ChREBP deficiency inhibits fructose-induced insulin resistance in pregnant mice and female offspring. Li J; Zhang S; Sun Y; Li J; Feng Z; Li H; Zhang M; Yan T; Han J; Duan Y EMBO Rep; 2024 Apr; 25(4):2097-2117. PubMed ID: 38532128 [TBL] [Abstract][Full Text] [Related]
5. The Roles of Carbohydrate Response Element Binding Protein in the Relationship between Carbohydrate Intake and Diseases. Iizuka K Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769488 [TBL] [Abstract][Full Text] [Related]
6. ChREBP regulates fructose-induced glucose production independently of insulin signaling. Kim MS; Krawczyk SA; Doridot L; Fowler AJ; Wang JX; Trauger SA; Noh HL; Kang HJ; Meissen JK; Blatnik M; Kim JK; Lai M; Herman MA J Clin Invest; 2016 Nov; 126(11):4372-4386. PubMed ID: 27669460 [TBL] [Abstract][Full Text] [Related]
7. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice. Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348 [TBL] [Abstract][Full Text] [Related]
8. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a. Lei Y; Hoogerland JA; Bloks VW; Bos T; Bleeker A; Wolters H; Wolters JC; Hijmans BS; van Dijk TH; Thomas R; van Weeghel M; Mithieux G; Houtkooper RH; de Bruin A; Rajas F; Kuipers F; Oosterveer MH Hepatology; 2020 Nov; 72(5):1638-1653. PubMed ID: 32083759 [TBL] [Abstract][Full Text] [Related]
9. Deletion of hepatic carbohydrate response element binding protein (ChREBP) impairs glucose homeostasis and hepatic insulin sensitivity in mice. Jois T; Chen W; Howard V; Harvey R; Youngs K; Thalmann C; Saha P; Chan L; Cowley MA; Sleeman MW Mol Metab; 2017 Nov; 6(11):1381-1394. PubMed ID: 29107286 [TBL] [Abstract][Full Text] [Related]
10. ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome. Iizuka K; Horikawa Y Endocr J; 2008 Aug; 55(4):617-24. PubMed ID: 18490833 [TBL] [Abstract][Full Text] [Related]
11. F6P/G6P-mediated ChREBP activation promotes the insulin resistance-driven hepatic lipid deposition in zebrafish. Gong Y; Lu Q; Xi L; Liu Y; Yang B; Su J; Liu H; Jin J; Zhang Z; Yang Y; Zhu X; Xie S; Han D J Nutr Biochem; 2023 Dec; 122():109452. PubMed ID: 37748621 [TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice. Zhao C; Liu L; Liu Q; Li F; Zhang L; Zhu F; Shao T; Barve S; Chen Y; Li X; McClain CJ; Feng W Mol Metab; 2019 Nov; 29():145-157. PubMed ID: 31668386 [TBL] [Abstract][Full Text] [Related]
13. Treatment with myo-inositol attenuates binding of the carbohydrate-responsive element-binding protein to the ChREBP-β and FASN genes in rat nonalcoholic fatty liver induced by high-fructose diet. Shimada M; Ichigo Y; Shirouchi B; Takashima S; Inagaki M; Nakagawa T; Hayakawa T Nutr Res; 2019 Apr; 64():49-55. PubMed ID: 30802722 [TBL] [Abstract][Full Text] [Related]
14. Growth hormone ameliorates high glucose-induced steatosis on in vitro cultured human HepG2 hepatocytes by inhibiting de novo lipogenesis via ChREBP and FAS suppression. Villanueva-Ortega E; Méndez-García LA; Garibay-Nieto GN; Laresgoiti-Servitje E; Medina-Bravo P; Olivos-García A; Muñoz-Ortega MH; Ventura-Juárez J; Escobedo G Growth Horm IGF Res; 2020; 53-54():101332. PubMed ID: 32698101 [TBL] [Abstract][Full Text] [Related]
15. A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. Fisher FM; Kim M; Doridot L; Cunniff JC; Parker TS; Levine DM; Hellerstein MK; Hudgins LC; Maratos-Flier E; Herman MA Mol Metab; 2017 Jan; 6(1):14-21. PubMed ID: 28123933 [TBL] [Abstract][Full Text] [Related]
16. Saccharin Increases Fasting Blood Glucose but Not Liver Insulin Resistance in Comparison to a High Fructose-Fed Rat Model. Leibowitz A; Bier A; Gilboa M; Peleg E; Barshack I; Grossman E Nutrients; 2018 Mar; 10(3):. PubMed ID: 29534506 [TBL] [Abstract][Full Text] [Related]
17. NF-κB p65 regulates hepatic lipogenesis by promoting nuclear entry of ChREBP in response to a high carbohydrate diet. Daniel PV; Dogra S; Rawat P; Choubey A; Khan AS; Rajak S; Kamthan M; Mondal P J Biol Chem; 2021; 296():100714. PubMed ID: 33930463 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of high-fat diet-induced obesity via reduction of ER-resident protein Nogo occurs through multiple mechanisms. Wang X; Yang Y; Zhao D; Zhang S; Chen Y; Chen Y; Feng K; Li X; Han J; Iwakiri Y; Duan Y; Yang X J Biol Chem; 2022 Feb; 298(2):101561. PubMed ID: 34998825 [TBL] [Abstract][Full Text] [Related]
20. High-Glucose or -Fructose Diet Cause Changes of the Gut Microbiota and Metabolic Disorders in Mice without Body Weight Change. Do MH; Lee E; Oh MJ; Kim Y; Park HY Nutrients; 2018 Jun; 10(6):. PubMed ID: 29899272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]